- Email: [email protected]
Gènes de glycosyl-hydrolases et leur utilisation pour la production d'enzymes de biodégradation de carraghénanes (T Barbeyron et al, FR)
of an animal to BSE, a kit for use in such an assessment and/or prediction method, a method for the treatment of a prion disease, compounds suitable for such a method, use of such compounds and pharmaceutical agents comprising such compounds. > Genetic markers and methods for the detection of Listenia monocytogenes and Listeria spp (JW Hazel and MA Jensen, US) El Du Pont de Nemours Co and the inventors N”W0 98/20160, PCT. A method, diagnostic sequences and primers are provided that are useful in identifying the LAterin monocytogenes and Listeriir spp. The method involves identifying an RAPD-amplified DNA fragment common to Listeria monocytogenes, then identifying the most conserved regions of that DNA fragments, and the preparing specific primers useful for detecting the presence of a marker within the fragments whereby that set of primers is then useful in the identification of all Listeria flzonoc>‘togenes. Markers within the same fragment that are specific to the Listeria genus are also identified and are useful for the identification of all Listerid spp.
infection by blocking HIV co-receptor RNA expression are provided. Ribozymcs which cleave HIV co-receptor RNA and inhibit HIV infection of cells are also provided. Co-receptor targets include fusin and CKRS. > Induction of Rev and Tat specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection (CA Van Baalen and AD Osterhaus, NL) Erasmus University Rotterdam and the inventors N” WO 98117309, PCT. The presence of cytotoxic Tcells to the Rev and/or Tat protein in samples from a subject infected with inmunodeficiency virus, particularly HIV in humans, is an indication of a stable disease condition and a favourable prognosis of lack of progression to disease. Immunogenic compositions containing at least one cytotoxic T-cell epitope of the Rev and/or Tat protein of an immunodeficiency virus, particularly HIV, or a vector encoding the T-cell rpitope, may be used to prevent infection by disease caused by the immunodeficiency virus, by stimulating, in the host, a specific cytotoxic T-cell response specific for the respective Rev and/or Tat proteins.
Virus Cancer > Inhibition of HIV replication using soluble Tat peptide analogs (F Kashanchi et a/, US) The Government of the United States of America, the Department of Health and Human Services and the inventors N” WO 98114587. PCT. Methods and compositions for inhibiting replication of HIV in a mammalian cell. The compositions can comprise soluble Tat peptide analogs, or a nucleic acid encoding such analogs, which inhibits transactivation of the HIV long terminal repeat. > Inhibiting HIV infection by cleaving co-receptor RNA (MC Leavitt et a/, US) lmmusol Inc and the inventors N” WO 98/17308, PCT. Methods of inhibiting HIV
> Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies (DJ Buchsbaum et al, US) The UAB Research Foundation N” WO 98118489, PCT. > Fragments d’anticorps & chaine unique anti-p53 et utilisations (L Bracco et L Debussche, FR) RhBne-Poulenc Rorer SA et les inventeurs N” WO 98118825, PCT. La prCsente invention concerne des anticorps i chaine unique dirig&s contre la protCine p.53, capables d’Ptre exprimt’s dans des cellules tumorales, capables de restaurer une fonction DNA binding 1~ zhro et une fonction d’activateur transcriptionnel in VIL’O. Elle
concerne kgalement les acides nucleiques codant ces mol&ules, les vecteurs les contenant et leurs utilisations. > Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof (GA Granger and T Gatanaga, US) The Regents of the University of California and the inventors N” WO 98120140. PCT.
Maladies infectieuses > Malarial binding site on duffy blood group protein (OA Pogo and A Chaudhuri, US) The New York Blood Center Inc N” WO 98121235, PCT. A composition and method for inhibiting binding of malarial Duffy-binding ligand to Duffy blood group antigens on mammalian erythrocytes is disclobed. The composition includes a Duffy-related peptide which interferes with binding between Duffy antigen expressed on erythrocyte cell surfaces and the Duffv-binding ligands of merozolres. r...) z Reversal of drug resistance through oligonucleotide complementary to Plasmodium falcipatvm specific region (RH Baker et al, US) Hybridon Inc and Worcester Foundation for Biomedical Research N” WO 98121323, PCT. The present invention provides methods of resensititing an anti-drug-resistant infectious agent to a drug. Also disclosed are synthetic oligonucleotides having a nucleotide sequence complementary to a region of pfmdrl nucleic acid, and methods of down-regulating the expression of pfwzdr nucleic acid using such oligonucleotides.
Maladies rteurodkgknflratives > Method for treating Alzheimer’s disease (AD Smith and KA Jobst, GB) Bristol-Myers Squibb Co N” WO 98/l 9690. PCT.
Enzymes > Thermostable DNA polymerase from Anaemce/lum thetmophilum (W Ankenbauer et al, DE, RU) Boehringer Mannheim GmbH and the inventors N” WO 98/14588, PCT. / A thermostable enzyme is provided which is derived from the microorgamsm Anaerocellwn
thermophilun~.
The enzyme has a molecular weight of 96 to 100 kDa, shows DNA polymerase activity and reverse transcriptase activity in the presence of magnesium ions. (...i z Ggnes de glycosyl-hydrolases et leur utilisation pour la production d’enzymes de biodegradation de carraghdnanes (T Barbeyron et a/, FR) Laboratoires Goemar SA et les inventeurs N” WO 98/l 5617, PCT. La prPsente invention a pour obiet des g?nes qui cadent des glycosyl-hvdrolases ayant un score HCA avec la iota-carraghenase d’illteromenus fortes qui est suptrieur ou t+gal i 65 %, sur le domain, s’etendant entre les acides amin& 164 et 3 I 1 de la sequence proteique SE(Z ID NO 2 de ladite iota-carraghPnase. ainsi que des g&es codant des glycosylhydrolases avant un score HCA avec la kappa-carraghtnase d’Alterormmzs cmri2geenolwrd qui est sup& ricur ou kgal j 7.5 ‘%I, sur le domaine s’ktendant entre les acides amines 1 I7 et 262 de la siquence prot&que SEQ ID NO 6 de ladite kappacarragh&ase. r Alpha-amylase fused to cellulose binding domain, for starch degradation (M Bjrarnvad et a/, DK) Novo Nordisk A/S and the inventors N” WO 98116633, PCT The invention relates to a starch conversion method wherein the starch substrate is treated in aqueous medium with a CBD/enzyme hybrid. Further, the invention also relates to an isolated DNA sequence encoding a stable CBD/enzyme hybrid, a DNA construct comprising said BIOFUTLIR 181
l
Septembre1998
49
infection by blocking HIV co-receptor RNA expression are provided. Ribozymcs which cleave HIV co-receptor RNA and inhibit HIV infection of cells are also provided. Co-receptor targets include fusin and CKRS. > Induction of Rev and Tat specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection (CA Van Baalen and AD Osterhaus, NL) Erasmus University Rotterdam and the inventors N” WO 98117309, PCT. The presence of cytotoxic Tcells to the Rev and/or Tat protein in samples from a subject infected with inmunodeficiency virus, particularly HIV in humans, is an indication of a stable disease condition and a favourable prognosis of lack of progression to disease. Immunogenic compositions containing at least one cytotoxic T-cell epitope of the Rev and/or Tat protein of an immunodeficiency virus, particularly HIV, or a vector encoding the T-cell rpitope, may be used to prevent infection by disease caused by the immunodeficiency virus, by stimulating, in the host, a specific cytotoxic T-cell response specific for the respective Rev and/or Tat proteins.
Virus Cancer > Inhibition of HIV replication using soluble Tat peptide analogs (F Kashanchi et a/, US) The Government of the United States of America, the Department of Health and Human Services and the inventors N” WO 98114587. PCT. Methods and compositions for inhibiting replication of HIV in a mammalian cell. The compositions can comprise soluble Tat peptide analogs, or a nucleic acid encoding such analogs, which inhibits transactivation of the HIV long terminal repeat. > Inhibiting HIV infection by cleaving co-receptor RNA (MC Leavitt et a/, US) lmmusol Inc and the inventors N” WO 98/17308, PCT. Methods of inhibiting HIV
> Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies (DJ Buchsbaum et al, US) The UAB Research Foundation N” WO 98118489, PCT. > Fragments d’anticorps & chaine unique anti-p53 et utilisations (L Bracco et L Debussche, FR) RhBne-Poulenc Rorer SA et les inventeurs N” WO 98118825, PCT. La prCsente invention concerne des anticorps i chaine unique dirig&s contre la protCine p.53, capables d’Ptre exprimt’s dans des cellules tumorales, capables de restaurer une fonction DNA binding 1~ zhro et une fonction d’activateur transcriptionnel in VIL’O. Elle
concerne kgalement les acides nucleiques codant ces mol&ules, les vecteurs les contenant et leurs utilisations. > Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof (GA Granger and T Gatanaga, US) The Regents of the University of California and the inventors N” WO 98120140. PCT.
Maladies infectieuses > Malarial binding site on duffy blood group protein (OA Pogo and A Chaudhuri, US) The New York Blood Center Inc N” WO 98121235, PCT. A composition and method for inhibiting binding of malarial Duffy-binding ligand to Duffy blood group antigens on mammalian erythrocytes is disclobed. The composition includes a Duffy-related peptide which interferes with binding between Duffy antigen expressed on erythrocyte cell surfaces and the Duffv-binding ligands of merozolres. r...) z Reversal of drug resistance through oligonucleotide complementary to Plasmodium falcipatvm specific region (RH Baker et al, US) Hybridon Inc and Worcester Foundation for Biomedical Research N” WO 98121323, PCT. The present invention provides methods of resensititing an anti-drug-resistant infectious agent to a drug. Also disclosed are synthetic oligonucleotides having a nucleotide sequence complementary to a region of pfmdrl nucleic acid, and methods of down-regulating the expression of pfwzdr nucleic acid using such oligonucleotides.
Maladies rteurodkgknflratives > Method for treating Alzheimer’s disease (AD Smith and KA Jobst, GB) Bristol-Myers Squibb Co N” WO 98/l 9690. PCT.
Enzymes > Thermostable DNA polymerase from Anaemce/lum thetmophilum (W Ankenbauer et al, DE, RU) Boehringer Mannheim GmbH and the inventors N” WO 98/14588, PCT. / A thermostable enzyme is provided which is derived from the microorgamsm Anaerocellwn
thermophilun~.
The enzyme has a molecular weight of 96 to 100 kDa, shows DNA polymerase activity and reverse transcriptase activity in the presence of magnesium ions. (...i z Ggnes de glycosyl-hydrolases et leur utilisation pour la production d’enzymes de biodegradation de carraghdnanes (T Barbeyron et a/, FR) Laboratoires Goemar SA et les inventeurs N” WO 98/l 5617, PCT. La prPsente invention a pour obiet des g?nes qui cadent des glycosyl-hvdrolases ayant un score HCA avec la iota-carraghenase d’illteromenus fortes qui est suptrieur ou t+gal i 65 %, sur le domain, s’etendant entre les acides amin& 164 et 3 I 1 de la sequence proteique SE(Z ID NO 2 de ladite iota-carraghPnase. ainsi que des g&es codant des glycosylhydrolases avant un score HCA avec la kappa-carraghtnase d’Alterormmzs cmri2geenolwrd qui est sup& ricur ou kgal j 7.5 ‘%I, sur le domaine s’ktendant entre les acides amines 1 I7 et 262 de la siquence prot&que SEQ ID NO 6 de ladite kappacarragh&ase. r Alpha-amylase fused to cellulose binding domain, for starch degradation (M Bjrarnvad et a/, DK) Novo Nordisk A/S and the inventors N” WO 98116633, PCT The invention relates to a starch conversion method wherein the starch substrate is treated in aqueous medium with a CBD/enzyme hybrid. Further, the invention also relates to an isolated DNA sequence encoding a stable CBD/enzyme hybrid, a DNA construct comprising said BIOFUTLIR 181
l
Septembre1998
49